Skip to main content

Table 1 Baseline Patient Demographic and Clinical Characteristics

From: Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study

Characteristic Groups P value Group1 (FTMDT) P value
1(FTMDT) 2(Conventional) Subgroup 1a Subgroup 1b
Age, years (M, IQR) 60 (53–66.5) 61 (54–69) 0.3415 61 (52–66) 60 (54–67) 0.7559
Gender, F/M (F%) 62/110 (36) 67/103 (39) 0.5210 30/57 (34) 32/53 (38) 0.6660
BMI, M (IQR) 22.6 (20.8–24.6) 22.67 (20.6–24.84) 0.9457 22.1 (21.2–24.8) 23.02 (20.65–24.55) 0.7215
ASA grade, n (%)    0.3920    0.6340
 I 156 (91) 148 (87)   78 (90) 78 (92)  
 II 16 (19) 21 (12)   9 (10) 7 (8)  
 III 0 (0) 1 (1)   0 (0) 0 (0)  
CEA, ng/mL, M (IQR) 6.7 (3.8–15.2) 5.6 (2.9–12.1) 0.3007 6.1 (3.1–12.9) 7.0 (4.8–20.8) 0.2561
CA199, U/mL, M, (IQR) 28.1 (7.0–77.8) 29.8 (7.0–51.0) 0.6492 16.8 (6.1–57.0) 28.3 (10.5–103.2) 0.1482
Site of Cancer, n (%)    0.5110    0.8810
 Ascending colon 31 (18) 35 (21)   18 (21) 13 (15)  
 Transverse colon 13 (8) 12 (7)   6 (7) 7 (8)  
 Descending colon 20 (12) 24 (14)   11 (13) 13 (15)  
 Sigmoid colon 50 (29) 38 (22)   24 (28) 26 (31)  
 Rectum 54 (33) 65 (36)   28 (32) 26 (31)  
Maximum tumor diameter, cm, M (IQR) 4 (3.5–5) 4 (3–5) 0.3358 4 (3–5) 5 (4–6) 0.0084
Pathologic type, n (%)       0.1400
 Adenocarcinoma 148 (86) 146 (86) 0.6260 73 (84) 75 (88)  
 Mucinous adenocarcinoma 9 (5) 13 (8)   6 (6.90) 3 (4)  
 Other 3 (2) 2 (1)   3 (3) 0 (0)  
 Missing 12 (7) 9 (5)   5 (6) 7(8)  
Differentiation, n (%)    0.3840    0.8480
 Well 20 (12) 20 (12)   11 (13) 9 (11)  
 Moderate 104 (60) 115 (68)   51 (59) 53 (62)  
 Poor 34 (20) 25 (15)   18 (21) 16 (19)  
 Missing 14 (8) 10 (5)   7 (8) 7 (8)  
Lymph nodes, M (IQR) 15 (11–20) 15 (12–18) 0.7319 14 (9–19) 16 (11–21) 0.3270
pT stage, n (%)    0.8070    0.0210
 1 9 (5) 9 (5)   7 (8) 2 (2)  
 2 27 (16) 22 (13)   11 (13) 16 (19)  
 3 91 (53) 96 (56)   53 (61) 38 (45)  
 4 33 (19) 28 (16)   11 (13) 22 (26)  
 Missing 12 (7) 15 (10)   5 (6) 7 (8)  
pN stage, n (%)    0.5360    0.5620
 0 97 (56) 88 (52)   48 (55) 49 (58)  
 1 39 (23) 46 (27)   23 (26) 16 (19)  
 2 25 (15) 21 (12)   12 (14) 13 (15)  
 Missing 11 (6) 15 (9)   4 (5) 7 (8)  
pTNM stage (n, %)    0.7110    0.6720
 I 27 (16) 23 (14)   13 (15) 14 (16)  
 II 66 (38) 63 (37)   32 (37) 34 (40)  
 III 66 (38) 69 (41)   36 (41) 30 (35)  
 IV 1 (1) 0 (0)   1 (1) 0 (0)  
 Missing 12 (7) 15 (8)   5 (6) 7 (9)  
  1. FTMDT Fast-track multi-discipline treatment, M (IQR) Median (interquartile range), F/M Female/male, F% Percent of females in subgroup, BMI Body mass index, ASA American Society of Anesthesiologists, n number, CEA Carcinoembryonic antigen, CA199 Carbohydrate antigen 19–9, pT pathological T stage, pN pathological N stage, pTNM pathological 7th edition TNM stage